Results 151 to 160 of about 4,120 (178)

Multi-omics therapeutic perspective on ACVR1 gene: from genetic alterations to potential targeting

Briefings in Functional Genomics, 2023
Shradheya R R Gupta, Indrakant K Singh, Archana Singh   +2 more
exaly  

ACVR1 Gene

2020
openaire   +1 more source

ANTI-ACVR1 ANTIBODIES AND USES THEREOF

2021
IDONE VINCENT J, HATSELL SARAH J, ECONOMIDES ARIS N   +2 more
openaire   +4 more sources

ACVR1 and Fibrodysplasia Ossificans Progressiva

2016
Frederick S. Kaplan, O. W. Towler, Eileen M. Shore   +2 more
openaire   +1 more source

Genomic Context and Mechanisms of the ACVR1 Mutation in Fibrodysplasia Ossificans Progressiva

Biomedicines, 2021
Renata Bocciardi, Ravazzolo Roberto, Bocciardi Renata   +2 more
exaly  

Faculty Opinions recommendation of ACVR1 antibodies exacerbate heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) by activating FOP-mutant ACVR1.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2022
openaire   +1 more source

ACVR1

2016
openaire   +1 more source

Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same

2020
WARNER STEVEN L, BEARSS DAVID J, SIDDIQUI-JAIN ADAM, WHATCOTT CLIFFORD J, FOULKS JASON MARC, ANTHONY STEPHEN PATRICK, FLYNN PAUL, FUJIWARA YUJI, ARIKAWA YUKA   +8 more
openaire   +3 more sources

The Type I BMP Receptor ACVR1/ALK2 is Required for Chondrogenesis During Development

Journal of Bone and Mineral Research, 2015
Karen Lyons, Teni Anbarchian
exaly  

ACVR1, a Therapeutic Target of Fibrodysplasia Ossificans Progressiva, Is Negatively Regulated by miR-148a

International Journal of Molecular Sciences, 2012
Hao Song, Deli Zhang, Xuesong Gao
exaly